Premature Labor (Tocolysis) - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Premature Labor (Tocolysis) - Pipeline Review, H1 2019’, provides an overview of the Premature Labor (Tocolysis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Premature Labor (Tocolysis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Premature Labor (Tocolysis) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Premature Labor (Tocolysis)

- The report reviews pipeline therapeutics for Premature Labor (Tocolysis) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Premature Labor (Tocolysis) therapeutics and enlists all their major and minor projects

- The report assesses Premature Labor (Tocolysis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Premature Labor (Tocolysis)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Premature Labor (Tocolysis)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Premature Labor (Tocolysis) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Dare Bioscience Inc

GlaxoSmithKline Plc

ObsEva SA

Dare Bioscience Inc

GlaxoSmithKline Plc

ObsEva SA

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Premature Labor (Tocolysis) – Overview

Premature Labor (Tocolysis) – Therapeutics ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Premature Labor (Tocolysis) – Overview

Premature Labor (Tocolysis) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Premature Labor (Tocolysis) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Premature Labor (Tocolysis) – Companies Involved in Therapeutics Development

Dare Bioscience Inc

GlaxoSmithKline Plc

ObsEva SA

Premature Labor (Tocolysis) – Drug Profiles

OBE-022 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

progesterone – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

retosiban – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Acute Inflammation and Premature Labor – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Premature Labor – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Premature Labor (Tocolysis) – Dormant Projects

Premature Labor (Tocolysis) – Discontinued Products

Premature Labor (Tocolysis) – Product Development Milestones

Featured News & Press Releases

Mar 13, 2019: ObsEva to present OBE022 clinical data for treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019

Jan 22, 2019: ObsEva SA reports initial good safety of OBE022 in pregnant women with preterm labour and announces start of part B of the PROLONG trial

Oct 30, 2018: Dare Bioscience to present preclinical data of DARE-FRT1 at AAPS 2018 meeting

Mar 01, 2018: ObsEva Announces Presentations Related to its Pre-term labor (PTL) Development Program at SRI 2018 Annual Meeting

Dec 05, 2017: ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor

Sep 11, 2017: ObsEva Announces Presentation Related to its PGF2a Receptor Antagonist at ACCP 2017 Annual Meeting

Jun 29, 2017: ObsEva Announces To Present on OBE022 at ESHRE 2017 Annual Meeting

May 18, 2017: ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with OBE022

Mar 17, 2017: ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor

Jan 13, 2017: ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor

Jul 28, 2016: ObsEva Initiates Phase 1 Clinical Program of OBE022, a First-in-Class Orally Active Prostaglandin F2a Antagonist, for the Treatment of Preterm Labor

Jan 11, 2016: Juniper Pharmaceuticals provides Update on JNP-0301

Nov 04, 2015: ObsEva Presents Pharmacology Data Showing that OBE002, the First Orally Active Prostaglandin F2a Antagonist, is devoid of the side effects associated with NSAID treatment of Preterm Labor

Mar 17, 2015: GSK announces start of phase III programme to evaluate retosiban for spontaneous preterm labour

Feb 27, 2012: Watson Receives Complete Response Letter From FDA For Progesterone Vaginal Gel 8%

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Premature Labor (Tocolysis), H1 2019

Number of Products under Development by Companies, H1 2019

Number of ...

List of Tables

Number of Products under Development for Premature Labor (Tocolysis), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Premature Labor (Tocolysis) – Pipeline by Dare Bioscience Inc, H1 2019

Premature Labor (Tocolysis) – Pipeline by GlaxoSmithKline Plc, H1 2019

Premature Labor (Tocolysis) – Pipeline by ObsEva SA, H1 2019

Premature Labor (Tocolysis) – Dormant Projects, H1 2019

Premature Labor (Tocolysis) – Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Premature Labor (Tocolysis), H1 2019

Number of Products under Development by Companies, H1 2019

Number of ...

List of Figures

Number of Products under Development for Premature Labor (Tocolysis), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports